ABT vs TMDX: fair value comparison
Abbott Laboratories and TransMedics Group, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, TMDX currently sits closer to the top of our discount ranking.
| ABT | TMDX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $101.95 | $82.24 |
| 12-month range | $87.78–$128.01 | $67.53–$150.42 |
| Sector rank | #35 of 113 Healthcare | #33 of 113 Healthcare |
| Quality grade | B | B |
| Momentum grade | — | B |
| Leverage | Moderate | High |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: ABT fair value analysis · TMDX fair value analysis